EU ATMP Rules for Longevity Clinics in 2026: Authorisation, Hospital Exemption, and Red Flags

Review note, August 28, 2026: This article now uses current EMA and EU legal sources. It removes unsupported country-level enforcement claims and corrects the status of Alofisel, whose EU marketing authorisation was withdrawn in December 2024.

Some longevity clinics advertise stem-cell, regenerative, or personalised cell procedures. Those marketing labels do not show whether a product is an advanced therapy medicinal product (ATMP), whether it is authorised, or whether a lawful exemption applies.

The European Medicines Agency’s current overview divides ATMPs into gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and products that combine an ATMP with a medical device.

Classification comes before marketing language. A somatic-cell product can fall within ATMP rules when cells have been substantially manipulated or are intended to perform a different essential function in the recipient than in the donor.

Three potential lawful pathways

1. An authorised medicinal product

ATMPs marketed across the EU use the central authorisation procedure. The EMA’s Committee for Advanced Therapies assesses quality, safety, and efficacy and gives a scientific recommendation before the European Commission’s authorisation decision.

A clinic should be able to provide the exact product name, authorised indication, manufacturer, product information, and patient eligibility. Authorisation for one indication does not establish benefit for general anti-ageing or another unapproved purpose.

2. An authorised clinical trial

An investigational ATMP may be administered in a properly authorised clinical trial. A patient should be able to identify the trial, sponsor, ethics process, protocol, eligibility criteria, and local investigator.

The EMA and national authorities warn that a therapy being described as experimental does not prove it is part of an authorised trial. A listing in a trial registry should be checked against the named intervention and treatment site.

3. The narrow hospital exemption

Article 28 of Regulation (EC) No 1394/2007 creates a national hospital exemption from central marketing authorisation. It is not a general commercial shortcut.

The regulation requires the product to be:

• prepared on a non-routine basis according to specific quality standards
• used in a hospital in the same Member State
• administered under the exclusive professional responsibility of a medical practitioner
• made for an individual patient under an individual medical prescription
• manufactured under authorisation from the Member State’s competent authority

National requirements must also be equivalent to the central system’s relevant quality, traceability, and pharmacovigilance standards. Because the exemption is administered nationally, the clinic should identify the competent authority and the specific authorisation it relies on.

Warning signs identified by European regulators

In March 2025, the EMA and Heads of Medicines Agencies warned that unregulated advanced therapies can expose patients to serious risks without proven benefits.

Their warning signs include:

• a product marketed as experimental outside an authorised clinical trial
• a provider unable to confirm approval by the EMA or a national competent authority
• benefit claims that go beyond available evidence

Before paying, request the product identity, regulatory pathway, authorisation number, manufacturing site, treating physician, hospital, traceability records, adverse-event contact, and follow-up plan.

A correction about Alofisel

Alofisel, a darvadstrocel cell therapy for complex perianal fistulas in Crohn’s disease, is sometimes cited as proof that a stem-cell product completed the EU authorisation process. That historical point is true, but its current status matters.

The EMA records that Alofisel’s marketing authorisation was withdrawn on December 13, 2024 at the holder’s request. It should not be presented as a currently authorised example in a 2026 clinic guide.

A six-question clinic check

1. What is the exact medicinal product and cell type?
2. Why does the provider believe it is, or is not, an ATMP?
3. Is the pathway central authorisation, an authorised trial, or a national hospital exemption?
4. Which EMA or national-authority record confirms that pathway?
5. Who is medically responsible and where will administration occur?
6. How are product traceability, adverse events, and long-term follow-up handled?

If the provider cannot answer those questions with documents, the phrase regenerative medicine is not enough to establish lawful or evidence-based care.

Main source: European Medicines Agency, Advanced therapy medicinal products: Overview, reviewed August 28, 2026. The hospital exemption requirements come from Regulation (EC) No 1394/2007 linked above.